Mipomersen (kynamro): a Novel Antisense Oligonucleotide Inhibitor for the Management of Homozygous Familial Hypercholesterolemia

Overview

Journal P T

Specialty Pharmacology

Date 2014 Mar 27

PMID 24669178

Citations 55

Authors

Elaine Wong

Tamara Goldberg

Affiliations

Soon will be listed here.

Abstract

Mipomersen (Kynamro) for homozygous familial hypercholesterolemia.

Citing Articles

Cancer theragnostics: closing the loop for advanced personalized cancer treatment through the platform integration of therapeutics and diagnostics.

Sergeeva O, Luo L, Guiseppi-Elie A Front Bioeng Biotechnol. 2025; 12:1499474.

PMID: 39898278 PMC: 11782185. DOI: 10.3389/fbioe.2024.1499474.

Development of bioconjugate-based delivery systems for nucleic acids.

Wahane A, Kasina V, Pathuri M, Marro-Wilson C, Gupta A, Slack F RNA. 2024; 31(1):1-13.

PMID: 39477529 PMC: 11648935. DOI: 10.1261/rna.080273.124.

Current status and trends in small nucleic acid drug development: Leading the future.

Miao Y, Fu C, Yu Z, Yu L, Tang Y, Wei M Acta Pharm Sin B. 2024; 14(9):3802-3817.

PMID: 39309508 PMC: 11413693. DOI: 10.1016/j.apsb.2024.05.008.

Characteristics, Physiopathology and Management of Dyslipidemias in Pregnancy: A Narrative Review.

Formisano E, Proietti E, Perrone G, Demarco V, Galoppi P, Stefanutti C Nutrients. 2024; 16(17).

PMID: 39275243 PMC: 11397408. DOI: 10.3390/nu16172927.

Therapeutic Antisense Oligonucleotides in Oncology: From Bench to Bedside.

Cakan E, Lara O, Szymanowska A, Bayraktar E, Chavez-Reyes A, Lopez-Berestein G Cancers (Basel). 2024; 16(17).

PMID: 39272802 PMC: 11394571. DOI: 10.3390/cancers16172940.

References

. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421. View

Kastelein J, Wedel M, Baker B, Su J, Bradley J, Yu R . Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation. 2006; 114(16):1729-35. DOI: 10.1161/CIRCULATIONAHA.105.606442. View

McGowan M, Tardif J, Ceska R, Burgess L, Soran H, Gouni-Berthold I . Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One. 2012; 7(11):e49006. PMC: 3496741. DOI: 10.1371/journal.pone.0049006. View

Yu R, Geary R, Flaim J, Riley G, Tribble D, vanVliet A . Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin Pharmacokinet. 2008; 48(1):39-50. DOI: 10.2165/0003088-200948010-00003. View

Raal F, Santos R, Blom D, Marais A, Charng M, Cromwell W . Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010; 375(9719):998-1006. DOI: 10.1016/S0140-6736(10)60284-X. View

Davis R . Cell and molecular biology of the assembly and secretion of apolipoprotein B-containing lipoproteins by the liver. Biochim Biophys Acta. 1999; 1440(1):1-31. DOI: 10.1016/s1388-1981(99)00083-9. View

Goldberg A . Novel therapies and new targets of treatment for familial hypercholesterolemia. J Clin Lipidol. 2010; 4(5):350-6. DOI: 10.1016/j.jacl.2010.08.015. View

Akdim F, Tribble D, Flaim J, Yu R, Su J, Geary R . Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. Eur Heart J. 2011; 32(21):2650-9. DOI: 10.1093/eurheartj/ehr148. View

Hovingh G, Davidson M, Kastelein J, OConnor A . Diagnosis and treatment of familial hypercholesterolaemia. Eur Heart J. 2013; 34(13):962-71. DOI: 10.1093/eurheartj/eht015. View

10.

Goldberg A, Hopkins P, Toth P, Ballantyne C, Rader D, Robinson J . Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011; 5(3):133-140. DOI: 10.1016/j.jacl.2011.03.001. View

11.

Dias N, Stein C . Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther. 2002; 1(5):347-55. View

12.

Stein E, Dufour R, Gagne C, Gaudet D, East C, Donovan J . Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery.... Circulation. 2012; 126(19):2283-92. DOI: 10.1161/CIRCULATIONAHA.112.104125. View

13.

Robinson J . Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Manag Care Pharm. 2013; 19(2):139-49. PMC: 10438186. DOI: 10.18553/jmcp.2013.19.2.139. View

14.

Ito M, McGowan M, Moriarty P . Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011; 5(3 Suppl):S38-45. DOI: 10.1016/j.jacl.2011.04.001. View

15.

Ricotta D, Frishman W . Mipomersen: a safe and effective antisense therapy adjunct to statins in patients with hypercholesterolemia. Cardiol Rev. 2012; 20(2):90-5. DOI: 10.1097/CRD.0b013e31823424be. View

16.

Thomas T, Ginsberg H . Development of apolipoprotein B antisense molecules as a therapy for hyperlipidemia. Curr Atheroscler Rep. 2010; 12(1):58-65. DOI: 10.1007/s11883-009-0078-7. View